# Merck & Co. Moat

Status: published. Policy: company-analysis-1.

Merck has a narrow moat from approved, differentiated medicines and vaccines and product-specific intellectual property. Approvals, commercial demand and selective realized price increases support a current advantage, but generic-driven sales losses demonstrate its finite durability. Pricing power is uneven and constrained by reimbursement, rebates and contractual commitments. Pipeline candidates and recent acquisitions could replenish the portfolio, but their future returns are not established.

## intangible_assets

Approved differentiated products and patent-backed exclusivity create product-specific barriers. Actual approvals and commercial demand support an existing advantage; they do not establish permanent portfolio leadership.

Durability: Limited and dependent on individual products and successful replenishment. New approvals demonstrate continued development capability, but the passages do not establish remaining protection periods for the principal earnings contributors.

Risks: Generic substitution has already caused severe Dificid erosion and reduced international Bridion demand. Other exclusivity losses, competing therapies, payer bargaining and agreed pricing restrictions can weaken both demand and economics. New approvals do not yet establish replacement earnings.

Invalidation: The portfolio-level narrow-moat judgment would fail if successive reporting periods showed generic-driven losses and price concessions overwhelming demand and commercial contributions from protected products and new launches. Failure of differentiated approvals to produce sustained commercial demand would also undermine the replenishment thesis.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm) · 2026-02-24
- [https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm](https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm) · 2026-08-07
- [https://www.sec.gov/Archives/edgar/data/310158/000119312526147704/d85708ddef14a.htm](https://www.sec.gov/Archives/edgar/data/310158/000119312526147704/d85708ddef14a.htm) · 2026-04-08

[JSON](https://beanvest.com/stock/mrk/moat.json)